ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On July17, 2017, Accuray Incorporated (the “Company”) issued a press release announcing certain preliminary estimated financial results for the Company for the quarter and year ended June30, 2017. A copy of the Company’s press release dated July17, 2017, titled “Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results,” is attached hereto as Exhibit99.1.

The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release dated July17, 2017, titled “Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results”


ACCURAY INC Exhibit
EX-99.1 2 a17-18024_1ex99d1.htm EX-99.1 Exhibit 99.1     Accuray Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results   Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash,…
To view the full exhibit click here

About ACCURAY INCORPORATED (NASDAQ:ARAY)

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.